Inventor · disambiguated record
Roman Galetto
Also filed as: GALETTO ROMAN · GALETTO ROMAN ARIEL
25 granted patents·19 pending applications·138 citations·filing 2010–2024
96Inventor score
Top patents by PatentIndex Score
44 records- 0196US11077144B2CD19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2020·Granted Aug 3, 2021·7 cites·17 claims
- 0296US9944702B2CD33 specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2015·Granted Apr 17, 2018·29 cites·29 claims
- 0395US10286007B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2017·Granted May 14, 2019·12 cites·18 claims
- 0495US9944709B2CD123 specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2015·Granted Apr 17, 2018·21 cites·19 claims
- 0594US11274316B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2021·Granted Mar 15, 2022·2 cites·5 claims
- 0694US10874693B2CD19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2014·Granted Dec 29, 2020·7 cites·11 claims
- 0792US10294304B2Chimeric antigen receptors targeting B-cell maturation antigenPFIZER·Filed 2016·Granted May 21, 2019·16 cites·22 claims
- 0891US10363270B2Methods for engineering allogeneic and immunosuppressive resistant T cell immunotherapyCELLECTIS·Filed 2017·Granted Jul 30, 2019·6 cites·7 claims
- 0991US10316101B2BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2015·Granted Jun 11, 2019·11 cites·20 claims
- 1090US10426795B2Use of preTalpha or functional variant thereof for expanding TCRalpha deficient T cellsCELLECTIS·Filed 2013·Granted Oct 1, 2019·8 cites·17 claims
- 1189US2024309397A1Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapyCELLECTIS·Filed 2023·Application pending·0 cites
- 1288US10378026B2RNA based method to obtain stably integrated retroviral vectorsCELLECTIS·Filed 2014·Granted Aug 13, 2019·6 cites·11 claims
- 1387US11304975B2Methods for engineering allogeneic and highly active t cell for immunotherapyCELLECTIS·Filed 2014·Granted Apr 19, 2022·4 cites·6 claims
- 1486US11891614B2Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapyCELLECTIS·Filed 2020·Granted Feb 6, 2024·1 cites·16 claims
- 1586US10517896B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2019·Granted Dec 31, 2019·2 cites·19 claims
- 1685US11396551B2Chimeric antigen receptors targeting CD70PFIZER·Filed 2019·Granted Jul 26, 2022·2 cites·47 claims
- 1782US11312782B2Chimeric antigen receptors targeting B-cell maturation antigenPFIZER·Filed 2019·Granted Apr 26, 2022·1 cites·46 claims
- 1882US2022177914A1Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cellsCELLECTIS·Filed 2022·Application pending·0 cites
- 1979US11498971B2BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2019·Granted Nov 15, 2022·1 cites·26 claims
- 2079US11414674B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2019·Granted Aug 16, 2022·0 cites·10 claims
- 2178US2025145725A1Chimeric antigen receptors targeting cd70PFIZER·Filed 2024·Application pending·0 cites
- 2277US11311575B2Methods for engineering highly active T cell for immunotherapyCELLECTIS·Filed 2014·Granted Apr 26, 2022·1 cites·15 claims
- 2377US11007224B2CD19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2020·Granted May 18, 2021·0 cites·10 claims
- 2476US10988541B2CD123 specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2018·Granted Apr 27, 2021·1 cites·18 claims
- 2576US2024182565A1Cd33 specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2023·Application pending·0 cites
- 2675US12152081B2Chimeric antigen receptors targeting CD70PFIZER·Filed 2022·Granted Nov 26, 2024·0 cites·42 claims
- 2773US11912776B2Chimeric antigen receptors targeting B-cell maturation antigenPFIZER·Filed 2022·Granted Feb 27, 2024·0 cites·24 claims
- 2873US2024269178A1Cd19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2023·Application pending·0 cites
- 2972US11603539B2Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapyCELLECTIS·Filed 2013·Granted Mar 14, 2023·0 cites·9 claims
- 3070US11919961B2CD123 specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2020·Granted Mar 5, 2024·0 cites·21 claims
- 3170US2023201260A1Methods for engineering allogeneic and highly active t cell for immunotheraphyCELLECTIS·Filed 2022·Application pending·0 cites
- 3270US2018360883A1Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapyCELLECTIS·Filed 2018·Application pending·0 cites
- 3367US2023050345A1Methods for engineering allogeneic and highly active t cell for immunotheraphyCELLECTIS·Filed 2022·Application pending·0 cites
- 3460US2023056268A1Methods for engineering highly active t cell for immunotheraphyCELLECTIS·Filed 2022·Application pending·0 cites
- 3559US2019359680A1Cs1 specific multi-chain chimeric antigen receptorCELLECTIS·Filed 2019·Application pending·0 cites
- 3657US2021000869A9Cd19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2019·Application pending·0 cites
- 3755US2019002561A1Cd33 specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2018·Application pending·0 cites
- 3852US2023228739A1Method for determining potency of chimeric antigen receptor expressing immune cellsCELLECTIS SA·Filed 2021·Application pending·0 cites
- 3952US2014178942A1Meganuclease variants cleaving at least one target in the genome of a retrovirus and uses thereofCELLECTIS·Filed 2013·Application pending·0 cites
- 4050US2015017136A1Methods for engineering allogeneic and highly active t cell for immunotherapyCELLECTIS·Filed 2013·Application pending·0 cites
- 4148US2012260356A1Meganuclease variants cleaving at least one target in the genome of a retrovirus and uses thereofCHOULIKA ANDRE·Filed 2010·Application pending·0 cites
- 4247US2017051037A1Cs1 specific multi-chain chimeric antigen receptorCELLECTIS·Filed 2015·Application pending·0 cites
- 4338US2018134795A1Cd123 specific multi-chain chimeric antigen receptorCELLECTIS·Filed 2015·Application pending·0 cites
- 4429US2018320138A1Process of gene-editing of cells isolated from a subject suffering from a metabolic disease affecting the erythroid lineage, cells obtained by said process and uses thereofCENTRO DE INVESTIG BIOMEDICA EN RED CIBER·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Roman Galetto files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →